EcoDrugPlus

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSCPBG00000007168
Gene Symbol: MET
1 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSCPBG00000002726
Gene Symbol: MPL
1 Cross references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSCPBG00000001407
Gene Symbol: MLST8
1 Cross references
203 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSCPBG00000027036
Gene Symbol: NQO1
1 Cross references
195 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nadph Oxidase 4

Ensembl ID : ENSCPBG00000019773
Gene Symbol: NOX4
1 Cross references
150 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSCPBG00000003397
Gene Symbol: NFE2L2
1 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Npc1 Like Intracellular Cholesterol Transporter 1

Ensembl ID : ENSCPBG00000024562
Gene Symbol: NPC1L1
1 Cross references
190 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-2 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCPBG00000017474
Gene Symbol: PIM2
1 Cross references
115 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCPBG00000021320
Gene Symbol: PIM3
1 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rar Related Orphan Receptor C

Ensembl ID : ENSCPBG00000008805
Gene Symbol: RORC
1 Cross references
383 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSCPBG00000023402
Gene Symbol: RELA
1 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ros Proto-Oncogene 1, Receptor Tyrosine Kinase

Ensembl ID : ENSCPBG00000018832
Gene Symbol: ROS1
1 Cross references
125 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).